BEAM

#1453
Beam Therapeutics Inc. Common Stock
28.46
-1.11%
Sector:
Básica:
Profit Currency:
Rango diario
28.46
28.46
Rango anual
13.52
36.44
Cambio diario
-1.11%
Monthly Change
-8.07%
6 month change
+67.41%
Cambio anual
+6.31%
Cierres anteriores
28.78
Open
28.46
Bid
Ask
Low
28.46
High
28.46
Volumen
220
Open full chart

Financials

Overview Statement Statistics Dividends
Quarterly Annual
  • Market Capitalization 2.81 B
  • Employee 510
  • Founded 2017
  • CEO John Evans
  • Website www.beamtx.com
  • Headquarter Delaware, United States
  • FIGI BBG00KXC8646
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-34.22
Price to sales ratio
19.62
Dividends per share
—
Dividend yield %
—

Beam Therapeutics Inc

Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks.

Noticias